Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › LCTX

Lineage Cell Therapeutics

LCTX Rare disease Lead: Phase 2 1 Biotech Distilled article ↓ 15 filings & releases ↓ Cash $37.4M (Jun 30, 2026) ↓ 1 verdict ↓
MetabolicNeurologyOphthalmology Cell

Market cap $258M 252.9M shares (10-Q, Aug 3, 2026) × $1.02 close Nov 6, 2026

Most recent annual filing: 2026-03-05

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. COR1 readout2026COR1 readout, 2026, notable
  2. OpRegen warrants corporate updateMay 21, 2028OpRegen warrants corporate update, May 21, 2028, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

Technology platforms

AlloSCOPE

Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering platform enabling large-scale manufacture of allogeneic cell therapies from a single pluripotent cell line; supports differentiation across multiple programs including ophthalmology (OpRegen, COR1), spinal cord injury (OPC1), auditory neuropathy (ReSonance/ANP1), and islet cell therapy (ILT1); AlloSCOPE 5D variant targets higher-scale production with reduced manipulation via fully suspension-based bioreactor process.

Factor Bioscience Gene-Editing Platform · Factor Bioscience

Patented gene-editing platform used to engineer hypoimmune iPSC lines for cell and gene therapy candidates; Lineage holds exclusive option and license to develop edited hypoimmune cell lines into differentiated cell transplant product candidates across a wide range of diseases

Discontinued (1)

Capital (as filed)

Cash
$37.4M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$13.5M Jun 30, 2026
Operating cash flow
−$7.2M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$50.8M cash, runway Q3 2028 per the deep dive of Aug 14, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Lineage Cell Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-08-17 Watch Lineage Cell Therapeutics (LCTX) — Scientific Deep Dive for OpRegen, OPC1, and Pipeline Products Strong biology and productive platform, but Lineage owns only ~half the economics of a lead asset it does not control on a timeline it cannot influence; revisit only on Roche's public disclosure of intent to advance OpRegen into a controlled multicenter Phase 2/3.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (15)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 8, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)